Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer's Disease Pathology

Rudi K. Tannenberg, Hadi Al. Shamaileh, Lasse Holm Lauridsen, Jagat R. Kanwar, Peter R. Dodd, Rakesh N. Veedu

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Deposition of amyloid-beta (A beta) peptides in the brain is a central event in the pathogenesis of Alzheimer's disease (AD), which makes A beta peptides a crucial target for therapeutic intervention. Significant efforts have been made towards the development of ligands that bind to A beta peptides with a goal of early detection of amyloid aggregation and the neutralization of A toxicity. Short single-stranded oligonucleotide aptamers bind with high affinity and specificity to their targets. Aptamers that specifically bind to A beta monomers, specifically the 40 and 42 amino acid species (A beta(1-40) and A beta(1-42)), fibrils and plaques have a great potential for diagnostic applications and the treatment of AD. Herein, we review the aptamers that bind to the various forms of A beta peptides for use in diagnosis and to inhibit plaque formation.
Original languageEnglish
JournalCurrent Alzheimer Research
Volume10
Issue number4
Pages (from-to)442
ISSN1567-2050
Publication statusPublished - 2013

Cite this

K. Tannenberg, R., Al. Shamaileh, H., Lauridsen, L. H., R. Kanwar, J., R. Dodd, P., & N. Veedu, R. (2013). Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer's Disease Pathology. Current Alzheimer Research, 10(4), 442.